Out of over 130 entrees from 18 European countries and 13 categories, we’re delighted to report that two winners are based at Stevenage Bioscience Catalyst!
Congratulations go to Quell Therapeutics who won the Deal of the Year >€500m award, and Complement Therapeutics who won the Series A - Finance Raise of the Year award, on 13th November at the prestigious ceremony held at Honourable Artillery Company, Chiswell Street, London.
The European Lifestars Awards, in partnership with LSX, the network for life science executive leaders, is an annual celebration of outstanding work contributing to the advancement of life sciences.
Quell Therapeutics won their Deal of the Year award for their $2+ billion partnership with AstraZeneca, sponsored by Baker McKenzie, to develop Treg cell therapies for Type 1 Diabetes and Inflammatory Bowel Disease. A spokesperson from Quell said on LinkedIn: “This award recognises the transformational value of this deal for both the company and wider industry and wouldn't have been possible without the hard work and dedication of our team. Congratulations also to the AstraZeneca deal team who partnered with us to get this collaboration together.”
Complement Therapeutics won the Series A Finance Raise of the Year Award sponsored by Cooley LLP, as a testament to the dedication and hard work their team over the past year. Their Chief Executive Office, Dr Rafiq Hasan said: "This award recognises the outstanding work from the entire Complement Therapeutics team as well as the groundbreaking science that forms the foundation of the Company. A great team driving great science!"
Operations Associate, Kansupa (Prong) Danchaivichit at Complement Therapeutics, added: “Receiving the Series A Raise of the Year is a testament to the dedication and hard work of our entire team over the past year. We are immensely grateful for the support of our investors and partners. Onwards and upwards!”
Photo credit: European Lifestars Awards and Complement Therapeutics.